Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 2/20 | 0.47 |
| ▸ | CA9 | Q16790 | 2/20 | 0.47 |
| ▸ | CA1 | P00915 | 1/20 | 0.47 |
| ▸ | CA3 | P07451 | 1/20 | 0.47 |
| ▸ | CA4 | P22748 | 1/20 | 0.47 |
| ▸ | CA6 | P23280 | 1/20 | 0.47 |
| ▸ | CA5A | P35218 | 1/20 | 0.47 |
| ▸ | CA7 | P43166 | 1/20 | 0.47 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.47 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.47 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.47 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.46 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 3/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | HPGD | P15428 | 2/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.42 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3793284 | 0.87 | CA12 (0.58) | CA12CA9CA1CA3CA4 | |
| SCHEMBL30480906 | 0.84 | CA12 (0.46) | CA12CA9CA1CA3CA4 | |
| SCHEMBL29018543 | 0.84 | CA12 (0.46) | CA12CA9CA1CA3CA4 | |
| SCHEMBL4440417 | 0.83 | KDM4E (0.59) | CA12CA9CA1CA3CA4 | |
| SCHEMBL30270565 | 0.83 | KDM4E (0.59) | CA12CA9CA1CA3CA4 | |
| SCHEMBL24125147 | 0.81 | CA12 (0.47) | CA12CA9CA1CA3CA4 | |
| SCHEMBL4435557 | 0.81 | LCK (0.47) | CA12CA9CA1CA3CA4 | |
| SCHEMBL15046545 | 0.81 | KIF11 (0.53) | CA12CA9CA1CA7CA14 | |
| SCHEMBL4434572 | 0.81 | CA12 (0.43) | CA12CA9CA1CA3CA4 | |
| SCHEMBL6419283 | 0.78 | PLG (0.51) | CYP2A6MAPTALDH1A1HPGDKIF11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130157996-A1 | TRPM8 ANTAGONISTS AND THEIR USE IN TREATMENTS | AMGEN INC. (US) | 2013-06-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130157996-A1 | TRPM8 ANTAGONISTS AND THEIR USE IN TREATMENTS | TRPM8, TRPM7, TRPM5 | CA12 2722/4885CA9 2291/4885CA1 1021/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.